Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 9/20 | 0.46 |
| ▸ | COMT | P21964 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670093 | 0.92 | FTO (0.56) | FTOCOMTCTSBMAPTLMNA | |
| SCHEMBL32670066 | 0.89 | FTO (0.47) | FTOCOMTCTSBMAPTALDH1A1 | |
| SCHEMBL32669920 | 0.82 | FTO (0.52) | FTOCOMTSMN1; SMN2CTSBMAPT | |
| SCHEMBL32670012 | 0.81 | FTO (0.57) | FTOCOMTLMNAKMT2A | |
| SCHEMBL32670064 | 0.81 | FTO (0.61) | FTOCOMTMAPTLMNAKDM4E | |
| SCHEMBL32669629 | 0.79 | COMT (0.33) | FTOCOMTMAPTMAPK1KMT2A | |
| SCHEMBL32669969 | 0.78 | FTO (0.50) | FTOCOMTSMN1; SMN2MAPTLMNA | |
| SCHEMBL32670146 | 0.78 | FTO (0.50) | FTOCOMTMAPTKDM4EALDH1A1 | |
| SCHEMBL32669984 | 0.77 | FTO (0.53) | FTOCOMTSMN1; SMN2CTSBPKM | |
| SCHEMBL32669750 | 0.76 | FTO (0.60) | FTOCOMTMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | FTO 1/4885COMT 52/4885SMN1; SMN2 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.